Wren is taking a transformative approach to drug discovery, targeting the fleeting intermediates that are central to many disease pathways but have been beyond the reach of conventional drug discovery approaches.

Our first focus is on two of the most prominent unmet medical needs of our time: Neurodegeneration in Alzheimer’s disease and Parkinson’s disease.

SIGN UP FOR UPDATES

Press Releases

March 29, 2023
Wren Presents Preclinical Data at AD/PD 2023 Demonstrating Potential of its First-in-Class, Small-Molecule Inhibitors of α-Synuclein Toxic Oligomers for the Treatment of Parkinson’s Disease
January 4, 2023
Wren Builds Out Scientific Advisory Board for Neurodegenerative Diseases
December 8, 2022
Wren Taps Vertex Veteran Executives and Other Leaders to Advance First-in-Class Small-Molecule Drugs into Clinical Testing for Neurodegenerative Diseases
March 4, 2022
Wren Appoints Bart Henderson as Chief Executive Officer
January 1, 2021
Wren Therapeutics Announces Financing of £12.4 Million (c. $17.0 Million)
November 1, 2020
Eisai and Wren Therapeutics Enter Into Research Collaboration Agreement for Drug Discovery for Synucleinopathies
September 1, 2020
Wren Therapeutics Announces Publication in Nature Research Journal
January 1, 2019
Wren Therapeutics Completes £18 Million Series A Financing
Back to Top